providers

The Future of Artificial Intelligence in Healthcare Artificial intelligence (AI) continues to transform the healthcare landscape, offering new ways to prevent, diagnose, and treat diseases. A recent study from Yale School of Medicine’s Cardiovascular Data Science Lab highlights AI’s potential to revolutionize heart failure risk stratification. Utilizing electrocardiogram (ECG) images, researchers have developed an AI-powered … Read more

Unveiling Inequities in Kidney Transplant Allocation: A Call for Change Recent research highlights critical inequities in kidney transplant allocation policies, especially impacting patients who began dialysis as children but were waitlisted as adults. This disparity, often referred to as the “pediatric advantage,” calls for urgent policy revisions to ensure equitable access to high-quality grafts for … Read more

The Evolving Landscape of GLP-1 RA Therapy and Its Implications for Thyroid Cancer As the global prevalence of type 2 diabetes (T2D) and obesity continues to rise, so too does the use of GLP-1 receptor agonists (GLP-1 RAs) for managing these conditions. A recent study published in JAMA Otolaryngol Head Neck Surg sheds light on … Read more

Understanding Emergency Department Use for Psoriatic Arthritis and Ankylosing Spondylitis Recent studies highlight a critical trend in healthcare where individuals with psoriatic arthritis (PsA) and ankylosing spondylitis (AS) often turn to emergency departments (EDs) for non-urgent issues. This recurring pattern shines a light on the accessibility challenges faced, particularly in rural areas, and the pressing … Read more

Fall Risks and COPD: Understanding the Connection New research indicates a significant association between high fall-risk increasing drug (FRID) burden and injurious falls among adults with chronic obstructive pulmonary disease (COPD) near the end of life.1 This study, led by Dr. Cara L. McDermott, reveals the complexities in managing COPD symptoms while minimizing the risk … Read more

The Evolving Landscape of Liver Disease Treatment: GLP-1 Receptor Agonists vs. SGLT2 Inhibitors Recent studies have spotlighted the effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) over sodium-glucose cotransporter-2 inhibitors (SGLT2i) in managing liver conditions associated with type 2 diabetes (T2D). This breakthrough has potential ramifications for the future of liver disease treatment, particularly for … Read more